Brief: PancreaSure Achieves 88% Sensitivity In Immunovia Study
10/06/2026 14:32
BRIEF-PancreaSure Achieves 88% Sensitivity In Immunovia Study June 10 (Reuters) - Immunovia AB (publ) IMMNOV.ST:
PANCREASURE ACHIEVES 88% SENSITIVITY, 98% SPECIFICITY IN AFFIRM STUDY
AFFIRM STUDY ENABLES BENCHMARKING OF PANCREASURE AGAINST OTHER TESTS
Source text: ID:nMFN8RmkC4
Further company coverage: IMMNOV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Immunovia AB (publ)
See all newsBrief: Immunovia Publishes Data On Pancreasure In Hereditary, Familial High-Risk Individuals
Brief: Immunovia To Carry Out Rights Issue Of About SEK 63 Million
Sweden's Immunovia Q2 sales rise on PancreaSure test uptake
Brief: Immunovia Reports Q2 Operating Loss Of SEK 22.8 Million
Brief: PancreaSure Achieves 88% Sensitivity In Immunovia Study